{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
fludrocortisone acetate
to a specific field?
Status:
Possibly Marketed Outside US
Source:
21 CFR 333C
(2015)
Source URL:
First approved in 2000
Source:
21 CFR 348
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
First approved in 1994
Source:
Sweat by JACKS MFG INC
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
G1 SPECIFIED SUBSTANCE
Status:
Other
Class:
G1 SPECIFIED SUBSTANCE
Status:
Other
Class:
G1 SPECIFIED SUBSTANCE
Status:
Possibly Marketed Outside US
Source:
BLA125773
(2024)
Source URL:
First approved in 2024
Source:
BLA125773
Source URL:
Class:
G1 SPECIFIED SUBSTANCE
Status:
Possibly Marketed Outside US
Source:
JBA Collagen-B by Advanced Pharmaceutical Services, Inc. Dba Affordable Quality Pharmaceuticals
(2021)
Source URL:
First approved in 2021
Source:
JBA Collagen-B by Advanced Pharmaceutical Services, Inc. Dba Affordable Quality Pharmaceuticals
Source URL:
Class:
G1 SPECIFIED SUBSTANCE
Status:
Possibly Marketed Outside US
Source:
ANDA206382
(1994)
Source URL:
First approved in 1994
Source:
ANDA206382
Source URL:
Class:
G1 SPECIFIED SUBSTANCE
Status:
Other
Class:
CONCEPT
Status:
US Approved Rx
(2024)
Source:
NDA217899
(2024)
Source URL:
First approved in 2024
Source:
NDA217899
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
MBX-8025 (Seladelpar) is an agonist of peroxisome proliferator-activated receptor delta. MBX-8025 improves insulin sensitivity and reverses dyslipidemia and hepatic storage of lipotoxic lipids to improve nonalcoholic steatohepatitis pathology in atherogenic diet-fed obese diabetic mice. MBX-8025 improves lipoprotein subfractions associated with atherogenic dyslipidemia. CymaBay Therapeutics is developing MBX-8025 for the treatment of patients with the autoimmune liver disease, primary biliary cholangitis and nonalcoholic steatohepatitis.
